Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

IDEAYA Biosciences, Inc. - Common Stock (NQ:IDYA)

24.42 +0.83 (+3.52%)
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 13, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about IDEAYA Biosciences, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >
Why IDEAYA Biosciences Shares Plunging Today
 
Via Benzinga
Dow Surges Over 100 Points; Crude Oil Falls Sharply
U.S. stocks traded turned higher midway through trading, with the Dow Jones gaining more than 100 points on Monday. 
Via Benzinga
Why Viridian Therapeutics Is Trading Higher By Around 58%, Here Are 67 Stocks Moving In Monday's Mid-Day Session
Gainers Sunrise New Energy Co. Ltd. (NASDAQ: EPOW) shares jumped 118.2% to $4.4948. Sunrise New Energy said that the company changed its name from Global Internet of the People, Inc. to Sunrise New... 
Via Benzinga
Recap: IDEAYA Biosciences Q1 Earnings
IDEAYA Biosciences (NASDAQ:IDYA) reported its Q1 earnings results on Tuesday, May 10, 2022 at 06:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
IDEAYA Advances IDE161 Into IND-Enabling Studies, Exercises Licensing Option For PARG Inhibitors
IDEAYA Biosciences Inc (NASDAQ: IDYA) has  
Via Benzinga
U.S. Stocks Edge Lower; NY Empire State Manufacturing Index Drops In August
U.S. stocks traded slightly lower this morning, with the Dow Jones dropping around 40 points on Monday. 
Via Benzinga
Recap: IDEAYA Biosciences Q2 Earnings
  IDEAYA Biosciences (NASDAQ:IDYA) reported its Q2 earnings results on Monday, August 15, 2022 at 06:00 AM. Here's what investors need to know about the announcement. Earnings IDEAYA Biosciences missed... 
Via Benzinga
Recap of Wednesday's Biotech Catalysts - End of The Day Summary
 
Via Benzinga
IDEAYA's Cancer Candidate Shows Early Tumor Modulation
 
Via Benzinga
Ideaya Nominates Potential First-In-Class Pol Theta Helicase Inhibitor In Collaboration With GSK
 
Via Benzinga
FDA Grants Orphan Drug Designation For IDEAYA's Darovasertib For Uveal Melanoma
The U.S. Food and Drug Administration (FDA) has granted orphan-drug designation to IDEAYA Biosciences (NASDAQ: IDYA) for its drug candidate Darovasertib for the treatment of uveal melanoma. 
Via Benzinga
Stocks That Hit 52-Week Lows On Wednesday
On Wednesday, 90 companies set new 52-week lows. Areas of Significance In Today's 52-Week Lows: The company with the largest market cap to set a new 52-week low was... 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Gainers Incannex Healthcare (NASDAQ:IXHL) stock moved upwards by 92.3% to $44.04 during Tuesday's pre-market session. The market value of their outstanding shares is... 
Via Benzinga
Ideaya Biosciences' IDE397 Shows Preliminary Tolerability In Early-Stage Solid Tumor Trial
IDEAYA Biosciences Inc (NASDAQ: IDYA) has announced  
Via Benzinga
The Daily Biotech Pulse: Biogen, Eisai Amend Aduhelm Agreement; Anaptys Acne Drug Flunks Midstage Study; Merck, AstraZeneca Discontinue Prostate Cancer Trial
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Recap: IDEAYA Biosciences Q4 Earnings
IDEAYA Biosciences (NASDAQ:IDYA) reported its Q4 earnings results on Tuesday, March 15, 2022 at 06:00 AM. Here's what investors need to know about the announcement.... 
Via Benzinga
Earnings Scheduled For March 15, 2022
Companies Reporting Before The Bell • IDEAYA Biosciences (NASDAQ:IDYA) is likely to report quarterly loss at $0.31 per share on revenue of $8.98 million. • Citi... 
Via Benzinga
IDEAYA Biosciences's Earnings: A Preview
IDEAYA Biosciences (NASDAQ:IDYA) is set to give its latest quarterly earnings report on Tuesday, 2022-03-15. Here's what investors need to know before the announcement. Analysts... 
Via Benzinga
IDEAYA Biosciences Inc. (NASDAQ: IDYA) Featured in Virtual Coverage of the 34th Annual Roth Conference
Via Investor Brand Network
The Week Ahead In Biotech (March 13-19): Bristol-Myers Squibb's Melanoma Drug Decision, Multiple Conference Presentations And Earnings Dominate Proceedings
Biotech stocks pulled back for a second week running, as the Ukraine war cast its cloud on the broader market. Dwindling earnings news flow and company-specific developments... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For March 10, 2022
Upgrades For Alpha Metallurgical Resources Inc (NYSE:AMR), B. Riley Securities upgraded the previous rating of Neutral to Buy. For the fourth quarter, Alpha Metallurgical... 
Via Benzinga
Stocks That Hit 52-Week Lows On Wednesday
Wednesday's session saw 107 companies set new 52-week lows. Points of Interest From Today's 52-Week Lows: Citigroup (NYSE:C) was the largest company by... 
Via Benzinga
Stocks That Hit 52-Week Lows On Thursday
On Thursday, 147 companies achieved new lows for the year. Significant Points From Today's 52-Week Lows: PayPal Holdings (NASDAQ:PYPL) was the biggest company... 
Via Benzinga
Stocks That Hit 52-Week Lows On Wednesday
On Wednesday, 115 companies reached new 52-week lows. Noteworthy Points From Today's 52-Week Lows: The largest company by market cap to hit a new 52-week low... 
Via Benzinga
Ideaya Reports New Data From Combo Therapy Regime In Pretreated Eye Cancer Patients
Ideaya Biosciences Inc (NASDAQ: IDYA) provided a clinical data update for the Phase 1/2 trial evaluating darovasertib and crizotinib synthetic lethal combination in... 
Via Benzinga
The Daily Biotech Pulse: Acadia Jumps On Data, vTv Shelves Psoriasis Study, More Setbacks For Merck's HIV Program, Decision Day For Daré
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Acadia Announces Positive Phase 3 Data For Trofinetide In Rett Syndrome... 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
Gainers TransCode Therapeutics (NASDAQ:RNAZ) stock rose 94.3% to $5.09 during Thursday's regular session. TransCode Therapeutics's stock is trading at a volume of... 
Via Benzinga
The Week Ahead In Biotech (Dec. 6-Dec. 11): Daré FDA Decision, Adcom Tryst For Reata, Multiple Conference Presentations And More
The omicron variant concerns were front and center in the markets in the week ended Dec. 3, and biotech stocks did not escape the brunt of selling in the wake of the negative... 
Via Benzinga
The Daily Biotech Pulse: Apellis Sinks On Data, Endo Shines On Opioid Litigation Settlement, T2 Biosystems Soars On Mutant Detection Ability of COVID Test
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 9) Adagio Therapeutics, Inc. (... 
Via Benzinga
The Daily Biotech Pulse: ProQR-Lilly R&D Partnership, Sanofi's Pemphigus Trial Disappointment, Humanigen's COVID-19 Drug Denied Emergency Use Authorization
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 8) Abbott Laboratories (NYSE:... 
Via Benzinga
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.